Previous Close | 0.2755 |
Open | 0.2909 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.2599 - 0.2909 |
52 Week Range | 0.2500 - 2.4190 |
Volume | |
Avg. Volume | 175,949 |
Market Cap | 3.029M |
Beta (5Y Monthly) | 0.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5900 |
Earnings Date | May 20, 2024 - May 24, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas. KetoAir™ is a cutting-edge breathalyzer featuring Hot App shareable techn
FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited (“Qi Diagnostics”) to distribute the KetoAir™, a breathalyzer device and related accessories, including current and future models, in key regions including North America, South America
FREEHOLD, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that it engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir™ in North America, South America, the United Kingdom (UK) and the European Union (EU). In April 2023, Avalon announced that it has partnered with Qi Diagnostics to excl